Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PalloV-CC
- Development stage
- Phase 1
- Lead developer
- LumaBridge
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
PalloV-CC is a particle-delivered, allogeneic tumor cell lysate vaccine designed for the neoadjuvant treatment of colon cancer. It consists of allogeneic tumor cell lysates delivered via a particle-based platform to stimulate an immune response against the tumor microenvironment. The vaccine is administered weekly via intradermal injection. It is being evaluated in Phase Ib clinical trials to assess safety, toxicity, and its impact on the tumor immune microenvironment in patients with endoscopic biopsy-proven colon cancer prior to surgical resection.
- Other names
- Particle-delivered, Allogeneic Tumor Cell Lysate Vaccine for Colon Cancer
Beyond the preview
Go deeper on PalloV-CC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PalloV-CC.